AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35660797 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab (anti-PD-1 monoclonal antibody), administered every 3 weeks for 6 months
Number of subjects: 12
Study 35660920 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma phylloquinone concentrations (tertile 2-3)
Number of subjects: 1208
Study 35660920 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower plasma phylloquinone concentrations with higher BMI
Number of subjects: 1208
Study 35661166 — intervention group
Group type: EXPERIMENTAL
Intervention: Teclistamab (1.5 mg/kg weekly after step-up doses of 0.06 mg and 0.3 mg per kg)
Number of subjects: 165
Study 35661166 — intervention group
Group type: EXPERIMENTAL
Intervention: Common adverse events
Number of subjects: 165
Study 35661239 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged QTc greater than 450 ms in infants with sensorineural hearing loss
Number of subjects: 40
Study 35661239 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal QTc intervals in infants with sensorineural hearing loss
Number of subjects: 40
Study 35661239 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing for long QT syndrome
Number of subjects: 40
Study 35661809 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35661896 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged running (98.8 ± 14.7 min, 21.2 ± 3.8 km, 4.7 ± 0.3 min/km)
Number of subjects: 28
Study 35662833 — intervention group
Group type: EXPERIMENTAL
Intervention: Masupirdine 50 mg
Number of subjects: 564
Study 35662833 — intervention group
Group type: EXPERIMENTAL
Intervention: Masupirdine 100 mg
Number of subjects: 564
Study 35662833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564
Study 35662954 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry supplementation for 12 weeks
Number of subjects: 60
Study 35662954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 35663154 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab (TCZ) therapy
Number of subjects: 337
Study 35663286 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane/Tazobactam (C/T)
Number of subjects: 100
Study 35663286 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 100
Study 35663767 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% urea cream
Number of subjects: 0
Study 35663767 — intervention group
Group type: COMPARATOR
Intervention: Basic moisturizer (vehicle cream)
Number of subjects: 0
Study 35663943 — intervention group
Group type: EXPERIMENTAL
Intervention: Efgartigimod
Number of subjects: 0
Study 35664159 — intervention group
Group type: EXPERIMENTAL
Intervention: face-to-face ACT + mobile application (app)
Number of subjects: 120
Study 35664159 — intervention group
Group type: EXPERIMENTAL
Intervention: face-to-face ACT
Number of subjects: 120
Study 35664159 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 120
Study 35664443 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose Vi-DT (n=252)
Number of subjects: 1800
Study 35664443 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidose Vi-DT (n=247)
Number of subjects: 1800
Study 35664443 — intervention group
Group type: COMPARATOR
Intervention: Meningococcal conjugate vaccine
Number of subjects: 1800
Study 35664760 — intervention group
Group type: EXPERIMENTAL
Intervention: supplemental home parenteral nutrition (sHPN)
Number of subjects: 0
Study 35664760 — intervention group
Group type: COMPARATOR
Intervention: non-sHPN (best practice nutritional care)
Number of subjects: 0
Study 35664765 — intervention group
Group type: EXPERIMENTAL
Intervention: HSPPC-96 vaccination
Number of subjects: 19
Study 35664997 — intervention group
Group type: EXPERIMENTAL
Intervention: PvDBPII/Matrix-M™ (delayed dosing regimen)
Number of subjects: 32
Study 35664997 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated controls
Number of subjects: 32
Study 35665323 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric impedance tomography (EIT) observation
Number of subjects: 2
Study 35665323 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP) recruitment
Number of subjects: 2
Study 35665323 — intervention group
Group type: EXPERIMENTAL
Intervention: EIT observation
Number of subjects: 2
Study 35665739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of autologous total IgG (50 mg, 8 injections over 4 weeks)
Number of subjects: 13
Study 35665826 — intervention group
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 1647
Study 35665826 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-environmental condition
Number of subjects: 1647
Study 35666066 — intervention group
Group type: EXPERIMENTAL
Intervention: Low haemoglobin levels
Number of subjects: 871
Study 35666066 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher haemoglobin levels (future investigation)
Number of subjects: 871
Study 35666146 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher prolactin levels at baseline
Number of subjects: 200
Study 35666146 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower circulating prolactin
Number of subjects: 200
Study 35666146 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing prolactin quartiles
Number of subjects: 200
Study 35666146 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who developed future T2D
Number of subjects: 200
Study 35666490 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model based on the International Standards for Neurological Classification of Spinal Cord Injury total motor score collected within 40 days from injury.
Number of subjects: 142
Study 35666490 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel outcome one year after SCI derived from the SCIM item 7 scores.
Number of subjects: 142
Study 35666538 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition transcranial direct current stimulation (HD-tDCS)
Number of subjects: 99
Study 35666538 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-responders)
Number of subjects: 99
Study 35666728 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen supplementation
Number of subjects: 75
Study 35666728 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilators
Number of subjects: 75
Study 35666728 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 75
Study 35666728 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of hospitalization (LOH)
Number of subjects: 75
Study 35666728 — intervention group
Group type: EXPERIMENTAL
Intervention: PES3 score
Number of subjects: 75
Study 35666728 — intervention group
Group type: EXPERIMENTAL
Intervention: Age <3 months
Number of subjects: 75
Study 35666882 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation intervention (8, 60-minute visits over 6 weeks)
Number of subjects: 73
Study 35666882 — intervention group
Group type: COMPARATOR
Intervention: In-person rehabilitation intervention (8, 60-minute visits over 6 weeks)
Number of subjects: 73
Study 35666951 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35667016 — intervention group
Group type: EXPERIMENTAL
Intervention: Befovacimab 100 mg
Number of subjects: 24
Study 35667016 — intervention group
Group type: EXPERIMENTAL
Intervention: Befovacimab 225 mg
Number of subjects: 24
Study 35667016 — intervention group
Group type: EXPERIMENTAL
Intervention: Befovacimab 400 mg
Number of subjects: 24
Study 35667016 — intervention group
Group type: EXPERIMENTAL
Intervention: Befovacimab (all doses)
Number of subjects: 24
Study 35667174 — intervention group
Group type: EXPERIMENTAL
Intervention: Wounds healing by secondary intention
Number of subjects: 55
Study 35667174 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant bacterial colonisation identified on bacterial fluorescence imaging
Number of subjects: 55
Study 35667271 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional Quality Improvement Program (QIP) including education, dietary counseling, and oral nutritional supplements (ONS) for daily intake over 60 days.
Number of subjects: 618
Study 35667399 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth physical therapy (PT)
Number of subjects: 126
Study 35667558 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine or mRNA-1273 vaccine, administered in two or three doses
Number of subjects: 138
Study 35667724 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote speech data collection using a smartphone app
Number of subjects: 225
Study 35667724 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote self-administered speech tasks
Number of subjects: 225
Study 35667724 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech tasks measuring executive control and voice quality
Number of subjects: 225
Study 35667724 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic features analysis (mel-frequency cepstrum coefficients, formant frequencies, intensity, loudness)
Number of subjects: 225
Study 35667724 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-based features analysis (number of words, noun and pronoun rate, idea density)
Number of subjects: 225
Study 35667792 — intervention group
Group type: EXPERIMENTAL
Intervention: Alarmin (double-stranded RNA [dsRNA])-activated Toll-like receptor signaling
Number of subjects: 0
Study 35667792 — intervention group
Group type: EXPERIMENTAL
Intervention: Host-microbe interaction-related immune pathways
Number of subjects: 0
Study 35667792 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutically modulating immune signaling
Number of subjects: 0
Study 35667900 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX-Persistent
Number of subjects: 671
Study 35667900 — intervention group
Group type: COMPARATOR
Intervention: MTX-Discontinued
Number of subjects: 671
Study 35668120 — intervention group
Group type: EXPERIMENTAL
Intervention: High-SFA diet (18%TE SFAs, 16%TE UFAs)
Number of subjects: 109
Study 35668120 — intervention group
Group type: COMPARATOR
Intervention: Low-SFA diet (10%TE SFAs, 24%TE UFAs)
Number of subjects: 109
Study 35668120 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary patterns analysis
Number of subjects: 109
Study 35668120 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma phospholipid fatty acid (PL-FA) profiles analysis
Number of subjects: 109
Study 35668129 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib
Number of subjects: 10
Study 35668167 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking mothers (nicotine exposure)
Number of subjects: 64
Study 35668167 — intervention group
Group type: COMPARATOR
Intervention: Nonsmoking mothers (control)
Number of subjects: 64
Study 35668295 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant zoster vaccine (RZV)
Number of subjects: 1000000
Study 35668295 — intervention group
Group type: COMPARATOR
Intervention: No vaccination
Number of subjects: 1000000
Study 35668388 — intervention group
Group type: EXPERIMENTAL
Intervention: Seminal miR19a levels
Number of subjects: 160
Study 35668388 — intervention group
Group type: EXPERIMENTAL
Intervention: Seminal miR19b levels
Number of subjects: 160
Study 35668388 — intervention group
Group type: EXPERIMENTAL
Intervention: Seminal miR34c levels
Number of subjects: 160
Study 35668388 — intervention group
Group type: EXPERIMENTAL
Intervention: Seminal miR133b levels
Number of subjects: 160
Study 35668470 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole exome sequencing of 9 cases with unexplained primary iron overload
Number of subjects: 27
Study 35668470 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanger sequencing of UBE2O and PCSK7 genes
Number of subjects: 27
Study 35668470 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro siRNA interference of UBE2O and PCSK7
Number of subjects: 27
Study 35668470 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenovirus generation of UBE2O p.K689R in cell lines
Number of subjects: 27
Study 35668496 — intervention group
Group type: EXPERIMENTAL
Intervention: TyG index T3 (7.77 ≤ TyG index ≤ 10.82)
Number of subjects: 731
Study 35668496 — intervention group
Group type: EXPERIMENTAL
Intervention: TyG index
Number of subjects: 731
Study 35668496 — intervention group
Group type: EXPERIMENTAL
Intervention: TyG index in patients with DM
Number of subjects: 731
Study 35668498 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiophobia assessment using Tampa Scale
Number of subjects: 200
Study 35668498 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar endurance assessment using Soren's lumbar extensor test
Number of subjects: 200
Study 35668498 — intervention group
Group type: EXPERIMENTAL
Intervention: Position sense assessment using lumbar repositioning test
Number of subjects: 200
Study 35668498 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity assessment using visual analog scale
Number of subjects: 200
Study 35668498 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional ability assessment using Patient-specific Functional Scale
Number of subjects: 200
Study 35668498 — intervention group
Group type: COMPARATOR
Intervention: Control group (asymptomatic individuals)
Number of subjects: 200
Study 35668702 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV-LRTI episodes
Number of subjects: 2401
Study 35668702 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence rates of first episode of RSV-LRTI
Number of subjects: 2401
Study 35668702 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV detection
Number of subjects: 2401
Study 35668702 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-detection of other viruses
Number of subjects: 2401
Study 35668874 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 0
Study 35669046 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-food diet based on the 2010 Dietary Guidelines for Americans (DGA)
Number of subjects: 44
Study 35669046 — intervention group
Group type: COMPARATOR
Intervention: Typical American diet (TAD)
Number of subjects: 44
Study 35669047 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary feeding social and behavior change communication (SBCC) intervention
Number of subjects: 0
Study 35669047 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 35669271 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride + memantine
Number of subjects: 36
Study 35669271 — intervention group
Group type: COMPARATOR
Intervention: Amisulpride + placebo
Number of subjects: 36
Study 35669398 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (10 mg/kg/day for 3 days)
Number of subjects: 80
Study 35669398 — intervention group
Group type: COMPARATOR
Intervention: Intravenous immunoglobulins (IVIG) (2 g/kg as a single dose)
Number of subjects: 80
Study 35669474 — intervention group
Group type: EXPERIMENTAL
Intervention: Podocan levels on admission
Number of subjects: 815
Study 35669478 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography and 3D printing guidance
Number of subjects: 166
Study 35669478 — intervention group
Group type: COMPARATOR
Intervention: Transthoracic echocardiography guidance
Number of subjects: 166
Study 35669478 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia for percutaneous procedures
Number of subjects: 166
Study 35669478 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia for transapical procedures
Number of subjects: 166
Study 35669478 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography and 3D printing
Number of subjects: 166
Study 35669484 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-month intervention combined with usual oncology care
Number of subjects: 0
Study 35669484 — intervention group
Group type: COMPARATOR
Intervention: Usual oncology care alone
Number of subjects: 0
Study 35669489 — intervention group
Group type: EXPERIMENTAL
Intervention: Tb-ERA test
Number of subjects: 200
Study 35669489 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 200
Study 35670217 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP (B-type NP)
Number of subjects: 2465
Study 35670217 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP (N-terminal pro-B-type NP)
Number of subjects: 2465
Study 35670217 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-proANP (midregional pro-atrial NP)
Number of subjects: 2465
Study 35670217 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP and NT-proBNP
Number of subjects: 2465
Study 35670217 — intervention group
Group type: COMPARATOR
Intervention: MR-proANP
Number of subjects: 2465
Study 35670263 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative functional urethral length (FUL)
Number of subjects: 43
Study 35670263 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative maximum urethral closure pressure (MUCP)
Number of subjects: 43
Study 35670715 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorine 18-labeled sodium fluoride (NaF) PET imaging
Number of subjects: 0
Study 35670715 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 0
Study 35671038 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab (300 mg) administered subcutaneously every 2 weeks
Number of subjects: 2561
Study 35671038 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab (300 mg) administered subcutaneously every 4 weeks
Number of subjects: 2561
Study 35671073 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype diagnostic decision support system
Number of subjects: 0
Study 35671073 — intervention group
Group type: COMPARATOR
Intervention: Usual care visits
Number of subjects: 0
Study 35671108 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine (30 mg/m2) on days 1-4, and pembrolizumab (200 mg i.v.) on day 5, every 21 days
Number of subjects: 35
Study 35671201 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab 3 or 10 mg/kg (Q4W for 6 doses/Q12W thereafter until discontinuation)
Number of subjects: 65
Study 35671201 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab 10 mg/kg (Q4W for 6 doses/Q12W for 3 doses) plus durvalumab 15 mg/kg (Q4W for 13 doses)
Number of subjects: 65
Study 35671201 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab 1 mg/kg (Q4W for 4 doses) plus durvalumab 20 mg/kg (Q4W for 4 doses followed by 10 mg/kg Q2W for 22 doses)
Number of subjects: 65
Study 35671201 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose tremelimumab 75 mg (Q4W for 4 doses) plus durvalumab 1500 mg (Q4W for 13 doses)
Number of subjects: 65
Study 35671201 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab 10 mg/kg (Q4W/Q12W)
Number of subjects: 65
Study 35671392 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplant (HCT) without preceding enzyme replacement therapy (ERT)
Number of subjects: 131
Study 35671392 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplant (HCT) preceded by enzyme replacement therapy (ERT-HCT)
Number of subjects: 131
Study 35671392 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy (GT) preceded by enzyme replacement therapy (ERT-GT)
Number of subjects: 131
Study 35671392 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplant (HCT)
Number of subjects: 131
Study 35671392 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplant (HCT) at <3.5 months of age
Number of subjects: 131
Study 35671392 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplant (HCT) at ≥3.5 months of age
Number of subjects: 131
Study 35671392 — intervention group
Group type: EXPERIMENTAL
Intervention: Active infection at the time of HCT
Number of subjects: 131
Study 35671392 — intervention group
Group type: EXPERIMENTAL
Intervention: No active infection at the time of HCT
Number of subjects: 131
Study 35671392 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched sibling and matched family donors (MSD/MFD)
Number of subjects: 131
Study 35671392 — intervention group
Group type: COMPARATOR
Intervention: HCT using a variety of transplant approaches and ERT-GT
Number of subjects: 131
Study 35671402 — intervention group
Group type: EXPERIMENTAL
Intervention: Toolkit provision including a guide, smartphone app, and video for administering walk tests.
Number of subjects: 54
Study 35671611 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-NRG® in canopy mode
Number of subjects: 85
Study 35671611 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-NRG® in face mask mode
Number of subjects: 85
Study 35672037 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision making during the COVID-19 pandemic
Number of subjects: 76
Study 35672037 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient treatment choices
Number of subjects: 76
Study 35672037 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician experiences during the pandemic
Number of subjects: 76
Study 35672071 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with TB
Number of subjects: 450
Study 35672071 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 450
Study 35672139 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC)
Number of subjects: 13454
Study 35672139 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive Ventilation (NIV)
Number of subjects: 13454
Study 35672139 — intervention group
Group type: COMPARATOR
Intervention: High-Flow Nasal Cannula (HFNC) or Noninvasive Ventilation (NIV)
Number of subjects: 13454
Study 35672221 — intervention group
Group type: EXPERIMENTAL
Intervention: EXIME® prosthesis
Number of subjects: 15
Study 35672221 — intervention group
Group type: COMPARATOR
Intervention: Self-catheterization (control group, not explicitly detailed in the abstract)
Number of subjects: 15
Study 35672552 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC (PrEP) initiated for participants meeting clinical criteria, dispensed through eHealth.
Number of subjects: 105
Study 35672552 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC (PrEP)
Number of subjects: 105
Study 35672552 — intervention group
Group type: EXPERIMENTAL
Intervention: Community outreach model via eHealth for PrEP delivery
Number of subjects: 105
Study 35672675 — intervention group
Group type: EXPERIMENTAL
Intervention: GCS-certified pancreatic cancer centers
Number of subjects: 45318
Study 35672675 — intervention group
Group type: COMPARATOR
Intervention: Non-certified hospitals
Number of subjects: 45318
Study 35672677 — intervention group
Group type: EXPERIMENTAL
Intervention: Larotrectinib
Number of subjects: 0